GoodRx (GDRX) Stock Forecast, Price Target & Predictions
GDRX Stock Forecast
GoodRx stock forecast is as follows: an average price target of $14.57 (represents a 91.96% upside from GDRX’s last price of $7.59) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.
GDRX Price Target
The average price target for GoodRx (GDRX) is $14.57 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $3.00. This represents a potential 91.96% upside from GDRX's last price of $7.59.
GDRX Analyst Ratings
According to 18 Wall Street analysts, GoodRx's rating consensus is 'Buy'. The analyst rating breakdown for GDRX stock is 1 'Strong Buy' (5.56%), 9 'Buy' (50.00%), 8 'Hold' (44.44%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
GoodRx Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 10, 2024 | Craig Hettenbach | Morgan Stanley | $9.50 | $8.55 | 11.11% | 25.16% |
| May 23, 2024 | Mark Mahaney | RBC Capital | $10.00 | $7.20 | 38.89% | 31.75% |
| May 16, 2024 | Stephanie Davis | Barclays | $9.00 | $8.06 | 11.66% | 18.58% |
| May 16, 2024 | Aaron Kessler | Raymond James | $10.00 | $7.27 | 37.55% | 31.75% |
| Apr 10, 2024 | Scott Schoenhaus | BOCOM International Holdings Company | $9.00 | $6.92 | 30.06% | 18.58% |
| Apr 10, 2024 | Scott Schoenhaus | KeyBanc | $9.00 | $6.74 | 33.53% | 18.58% |
| Mar 25, 2024 | Stan Berenshteyn | Wells Fargo | $10.00 | $7.23 | 38.39% | 31.75% |
| Nov 13, 2023 | Eric Sheridan | Goldman Sachs | $3.00 | $4.73 | -36.58% | -60.47% |
| Dec 01, 2022 | - | Citigroup | $7.00 | $4.36 | 60.55% | -7.77% |
| Aug 09, 2022 | Steve Valiquette | Barclays | $13.00 | $7.76 | 67.53% | 71.28% |
The latest GoodRx stock forecast, released on Jun 10, 2024 by Craig Hettenbach from Morgan Stanley, set a price target of $9.50, which represents a 11.11% increase from the stock price at the time of the forecast ($8.55), and a 25.16% increase from GDRX last price ($7.59).
GoodRx Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 8 |
| Avg Price Target | - | - | $8.69 |
| Last Closing Price | $7.59 | $7.59 | $7.59 |
| Upside/Downside | -100.00% | -100.00% | 14.49% |
In the current month, the average price target of GoodRx stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to GoodRx's last price of $7.59. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 16, 2024 | UBS | Buy | Buy | Hold |
| Aug 09, 2024 | Raymond James | Outperform | Strong Buy | Upgrade |
| Jun 10, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| May 23, 2024 | RBC Capital | Sector Perform | Outperform | Upgrade |
| May 16, 2024 | Barclays | Overweight | Overweight | Hold |
| May 16, 2024 | UBS | Underperform | Underperform | Hold |
| May 16, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| May 16, 2024 | KeyBanc | Overweight | Overweight | Hold |
| May 16, 2024 | Raymond James | Strong Buy | Outperform | Upgrade |
| May 09, 2024 | Cowen & Co. | Buy | Buy | Hold |
GoodRx's last stock rating was published by UBS on Aug 16, 2024. The company gave GDRX a "Buy" rating, the same as its previous rate.
GoodRx Financial Forecast
GoodRx Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $196.64M | $179.96M | $189.68M | $183.99M | $184.11M | $187.32M | - | $203.33M | $213.26M | $195.10M | $176.63M | $160.43M | $153.54M | $140.45M |
| Avg Forecast | $252.68M | $241.30M | $243.52M | $238.50M | $228.91M | $219.89M | $218.42M | $211.86M | $206.38M | $195.65M | $200.47M | $196.11M | $194.30M | $188.52M | $186.84M | $182.09M | $178.50M | $185.04M | $184.71M | $200.45M | $217.46M | $194.78M | $174.58M | $160.62M | $147.82M | $135.07M |
| High Forecast | $254.59M | $243.13M | $245.37M | $240.31M | $230.64M | $221.55M | $220.07M | $213.47M | $207.94M | $196.74M | $201.98M | $197.60M | $194.74M | $189.95M | $188.25M | $183.47M | $179.85M | $186.44M | $184.71M | $203.74M | $221.02M | $197.98M | $177.45M | $163.26M | $150.25M | $137.29M |
| Low Forecast | $251.31M | $239.99M | $242.20M | $237.21M | $227.67M | $218.70M | $217.23M | $210.72M | $205.26M | $195.24M | $199.38M | $195.05M | $193.12M | $187.50M | $185.83M | $181.10M | $177.53M | $184.04M | $184.71M | $197.61M | $214.37M | $192.02M | $172.11M | $158.35M | $145.73M | $133.16M |
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 8 | 6 | 5 | 5 | 8 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 0.95% | 1.02% | 1.01% | 1.03% | 1.01% | - | 1.01% | 0.98% | 1.00% | 1.01% | 1.00% | 1.04% | 1.04% |
GoodRx's average Quarter revenue forecast for Mar 24 based on 4 analysts is $196.11M, with a low forecast of $195.05M, and a high forecast of $197.60M. GDRX's average Quarter revenue forecast represents a -0.27% decrease compared to the company's last Quarter revenue of $196.64M (Dec 23).
GoodRx EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 8 | 6 | 5 | 5 | 8 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $1.68M | $-12.09M | $42.22M | $31.67M | $22.71M | $1.16M | - | $31.19M | $22.42M | $17.17M | $8.03M | $379.00K | $-295.01M | $-56.50M |
| Avg Forecast | $14.60M | $13.95M | $14.07M | $13.78M | $13.23M | $12.71M | $12.62M | $12.24M | $11.93M | $11.31M | $11.59M | $37.43M | $11.23M | $10.90M | $10.80M | $29.59M | $10.32M | $43.35M | $10.67M | $23.39M | $24.66M | $46.37M | $14.46M | $379.00K | $8.54M | $-49.44M |
| High Forecast | $14.71M | $14.05M | $14.18M | $13.89M | $13.33M | $12.80M | $12.72M | $12.34M | $12.02M | $11.37M | $11.67M | $44.91M | $11.25M | $10.98M | $10.88M | $35.51M | $10.39M | $52.02M | $10.67M | $28.07M | $29.60M | $55.64M | $17.35M | $454.80K | $8.68M | $-39.55M |
| Low Forecast | $14.52M | $13.87M | $14.00M | $13.71M | $13.16M | $12.64M | $12.55M | $12.18M | $11.86M | $11.28M | $11.52M | $29.94M | $11.16M | $10.84M | $10.74M | $23.67M | $10.26M | $34.68M | $10.67M | $18.71M | $19.73M | $37.09M | $11.56M | $303.20K | $8.42M | $-59.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.15% | -1.11% | 3.91% | 1.07% | 2.20% | 0.03% | - | 1.33% | 0.91% | 0.37% | 0.56% | 1.00% | -34.53% | 1.14% |
4 analysts predict GDRX's average Quarter EBITDA for Mar 24 to be $37.43M, with a high of $44.91M and a low of $29.94M. This is 2122.59% upper than GoodRx's previous annual EBITDA (Dec 23) of $1.68M.
GoodRx Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 8 | 6 | 5 | 5 | 8 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-25.87M | $-38.49M | $58.79M | $-3.29M | $-1.97M | $-41.73M | - | $12.29M | $-39.91M | $-18.07M | $31.06M | $1.67M | $-298.27M | $-50.03M |
| Avg Forecast | $55.70M | $52.84M | $54.03M | $50.56M | $49.41M | $45.58M | $43.05M | $39.36M | $36.27M | $33.45M | $33.46M | $14.75M | $25.97M | $22.35M | $23.29M | $11.66M | $17.71M | $-45.62M | $15.38M | $9.22M | $-43.91M | $-48.79M | $55.91M | $1.67M | $26.31M | $-43.78M |
| High Forecast | $56.24M | $53.36M | $54.56M | $51.05M | $49.90M | $46.02M | $43.47M | $39.75M | $36.63M | $37.17M | $33.78M | $17.70M | $32.46M | $22.57M | $23.51M | $14.00M | $17.89M | $-36.49M | $15.38M | $11.06M | $-35.12M | $-39.03M | $67.09M | $2.00M | $26.87M | $-35.02M |
| Low Forecast | $55.31M | $52.47M | $53.65M | $50.20M | $49.07M | $45.26M | $42.74M | $39.08M | $36.02M | $29.73M | $33.22M | $11.80M | $19.48M | $22.20M | $23.12M | $9.33M | $17.59M | $-54.74M | $15.38M | $7.38M | $-52.69M | $-58.54M | $44.73M | $1.33M | $25.82M | $-52.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -1.00% | -1.72% | 2.52% | -0.28% | -0.11% | 0.91% | - | 1.33% | 0.91% | 0.37% | 0.56% | 1.00% | -11.34% | 1.14% |
GoodRx's average Quarter net income forecast for Sep 23 is $22.35M, with a range of $22.20M to $22.57M. GDRX's average Quarter net income forecast represents a -61.97% decrease compared to the company's last Quarter net income of $58.79M (Jun 23).
GoodRx SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 8 | 6 | 5 | 5 | 8 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $124.12M | $126.93M | $107.65M | $108.14M | $112.71M | $135.76M | - | $124.87M | $141.87M | $131.60M | $127.96M | $123.48M | $415.69M | $173.59M |
| Avg Forecast | $186.05M | $177.67M | $179.30M | $175.61M | $168.54M | $161.90M | $160.82M | $155.99M | $151.95M | $144.05M | $147.60M | $149.87M | $143.06M | $138.81M | $137.57M | $118.47M | $131.43M | $136.24M | $136.00M | $93.65M | $156.05M | $143.42M | $128.54M | $123.48M | $108.84M | $99.45M |
| High Forecast | $187.45M | $179.01M | $180.66M | $176.94M | $169.82M | $163.13M | $162.04M | $157.17M | $153.10M | $144.86M | $148.72M | $179.84M | $143.39M | $139.86M | $138.61M | $142.17M | $132.42M | $137.27M | $136.00M | $112.39M | $187.26M | $145.77M | $130.65M | $148.18M | $110.63M | $101.08M |
| Low Forecast | $185.04M | $176.71M | $178.33M | $174.66M | $167.63M | $161.02M | $159.95M | $155.15M | $151.13M | $143.75M | $146.80M | $119.89M | $142.19M | $138.06M | $136.82M | $94.78M | $130.71M | $135.51M | $136.00M | $74.92M | $124.84M | $141.38M | $126.72M | $98.78M | $107.30M | $98.04M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 0.91% | 0.78% | 0.91% | 0.86% | 1.00% | - | 1.33% | 0.91% | 0.92% | 1.00% | 1.00% | 3.82% | 1.75% |
GoodRx's average Quarter SG&A projection for Mar 24 is $149.87M, based on 4 Wall Street analysts, with a range of $119.89M to $179.84M. The forecast indicates a 20.74% rise compared to GDRX last annual SG&A of $124.12M (Dec 23).
GoodRx EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 5 | 8 | 6 | 5 | 5 | 8 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.06 | $-0.09 | $0.14 | $-0.01 | $-0.00 | $-0.10 | - | $0.03 | $-0.10 | $-0.04 | $0.08 | - | $-0.74 | $-0.21 |
| Avg Forecast | $0.14 | $0.14 | $0.14 | $0.13 | $0.13 | $0.12 | $0.11 | $0.10 | $0.09 | $0.09 | $0.09 | $0.07 | $0.07 | $0.06 | $0.06 | $0.06 | $0.05 | $0.04 | $0.04 | $0.08 | $0.10 | $0.09 | $0.08 | $0.07 | $0.07 | $0.08 |
| High Forecast | $0.15 | $0.14 | $0.14 | $0.13 | $0.13 | $0.12 | $0.11 | $0.10 | $0.10 | $0.10 | $0.09 | $0.07 | $0.08 | $0.06 | $0.06 | $0.06 | $0.05 | $0.04 | $0.04 | $0.08 | $0.10 | $0.09 | $0.08 | $0.07 | $0.07 | $0.08 |
| Low Forecast | $0.14 | $0.14 | $0.14 | $0.13 | $0.13 | $0.12 | $0.11 | $0.10 | $0.09 | $0.08 | $0.09 | $0.07 | $0.05 | $0.06 | $0.06 | $0.06 | $0.05 | $0.04 | $0.04 | $0.08 | $0.10 | $0.09 | $0.08 | $0.07 | $0.06 | $0.07 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.95% | -1.60% | 2.31% | -0.14% | -0.10% | -2.36% | - | 0.37% | -0.98% | -0.46% | 1.02% | 0.06% | -11.34% | -2.77% |
According to 4 Wall Street analysts, GoodRx's projected average Quarter EPS for Sep 23 is $0.06, with a low estimate of $0.06 and a high estimate of $0.06. This represents a -58.50% decrease compared to GDRX previous annual EPS of $0.14 (Jun 23).
GoodRx Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TDOC | Teladoc Health | $9.11 | $52.65 | 477.94% | Hold |
| ACCD | Accolade | $4.31 | $14.81 | 243.62% | Buy |
| HCAT | Health Catalyst | $8.70 | $29.25 | 236.21% | Buy |
| CERT | Certara | $10.83 | $21.75 | 100.83% | Hold |
| DH | Definitive Healthcare | $4.74 | $9.50 | 100.42% | Hold |
| GDRX | GoodRx | $7.59 | $14.57 | 91.96% | Buy |
| PRVA | Privia Health Group | $18.80 | $33.82 | 79.89% | Buy |
| SLP | Simulations Plus | $31.89 | $56.00 | 75.60% | Buy |
| EVH | Evolent Health | $30.54 | $44.00 | 44.07% | Buy |
| TXG | 10x Genomics | $21.41 | $30.20 | 41.06% | Hold |
| SDGR | Schrödinger | $19.62 | $27.33 | 39.30% | Buy |
| PGNY | Progyny | $24.82 | $34.50 | 39.00% | Hold |
| TALK | Talkspace | $2.17 | $2.50 | 15.21% | Hold |
| GEHC | GE HealthCare | $86.79 | $93.88 | 8.17% | Buy |
| VEEV | Veeva Systems | $214.80 | $229.50 | 6.84% | Buy |
| AMWL | American Well | $10.15 | $8.40 | -17.24% | Hold |
| DOCS | Doximity | $40.16 | $32.17 | -19.90% | Buy |
GDRX Forecast FAQ
Is GoodRx a good buy?
Yes, according to 18 Wall Street analysts, GoodRx (GDRX) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 9 'Buy' recommendations, accounting for 55.56% of GDRX's total ratings.
What is GDRX's price target?
GoodRx (GDRX) average price target is $14.57 with a range of $3 to $45, implying a 91.96% from its last price of $7.59. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will GoodRx stock go up soon?
According to Wall Street analysts' prediction for GDRX stock, the company can go up by 91.96% (from the last price of $7.59 to the average price target of $14.57), up by 492.89% based on the highest stock price target, and down by -60.47% based on the lowest stock price target.
Can GoodRx stock reach $11?
GDRX's average twelve months analyst stock price target of $14.57 supports the claim that GoodRx can reach $11 in the near future.
What are GoodRx's analysts' financial forecasts?
GoodRx's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $879.08M (high $885.73M, low $874.31M), average EBITDA is $50.8M (high $51.19M, low $50.53M), average net income is $177.4M (high $179.14M, low $176.15M), average SG&A $647.26M (high $652.15M, low $643.75M), and average EPS is $0.461 (high $0.466, low $0.458). GDRX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $976.01M (high $983.39M, low $970.72M), average EBITDA is $56.41M (high $56.83M, low $56.1M), average net income is $213.12M (high $215.22M, low $211.62M), average SG&A $718.63M (high $724.06M, low $714.73M), and average EPS is $0.554 (high $0.559, low $0.55).
Did the GDRX's actual financial results beat the analysts' financial forecasts?
Based on GoodRx's last annual report (Dec 2023), the company's revenue was $750.26M, which missed the average analysts forecast of $751.76M by -0.20%. Apple's EBITDA was $-4.632M, missing the average prediction of $62.51M by -107.41%. The company's net income was $-102M, missing the average estimation of $83.27M by -222.82%. Apple's SG&A was $466.84M, missing the average forecast of $537.92M by -13.21%. Lastly, the company's EPS was $-0.25, missing the average prediction of $0.242 by -203.29%. In terms of the last quarterly report (Dec 2023), GoodRx's revenue was $196.64M, beating the average analysts' forecast of $194.3M by 1.21%. The company's EBITDA was $1.68M, missing the average prediction of $11.23M by -85.00%. GoodRx's net income was $-25.869M, missing the average estimation of $25.97M by -199.61%. The company's SG&A was $124.12M, missing the average forecast of $143.06M by -13.24%. Lastly, the company's EPS was $-0.0642, missing the average prediction of $0.0675 by -195.11%